<?xml version="1.0" encoding="UTF-8"?>
<p>Anlotinib is a multitargeting TKI that can significantly inhibit tumor proliferation, vasculature, and the tumor microenvironment by selectively targeting VEGFR-2,-3, FGFR-1,-2,-3,-4, PDGFRα/β, C-Kit, Ret, Aurora-B, c-FMS, and DDR1 (
 <xref rid="B7" ref-type="bibr">7</xref>). A phase I study showed that anlotinib has promising anti-tumor potential against a variety of tumors, including STS and NSCLC (
 <xref rid="B18" ref-type="bibr">18</xref>). At present, anlotinib has been approved as a second- or later-line treatment for STS and third- or later-line treatment for NSCLC based on the ALTER 0203 and ALTER 0303 clinical trials in China (
 <xref rid="B8" ref-type="bibr">8</xref>, 
 <xref rid="B9" ref-type="bibr">9</xref>). Considering that NGS for this patient revealed a few gene mutations, including of the FGFR gene, we combined chemotherapy with anlotinib, which selectively targets FGFR, and achieved prominent tumor regression and a long PFS without evident toxicity.
</p>
